Pyxis Oncology director granted 45,867 options

Pyxis Oncology, Inc. director Palani Santhosh received a grant of stock options covering 45,867 shares of common stock.

Accepted by SEC EDGAR 03/25/2026 - 05:04 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Pyxis Oncology, Inc. director Palani Santhosh received a grant of stock options covering 45,867 shares of common stock. The options carry an exercise price of $1.36 per share and expire on March 24, 2036. All 45,867 options will vest 100% on the first anniversary of the grant date, conditioned on his continued service through that vesting date. Following this grant, he holds 45,867 stock options directly.

Insider Trade Summary

Grant/Award: 45,867 shares

Grant/Award 1 txn

Insider Palani Santhosh

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	45,867	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 45,867 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pyxis Oncology (PYXS) report for Palani Santhosh?

Pyxis Oncology reported that director Palani Santhosh received a grant of 45,867 stock options. These options give him the right to buy common shares at a fixed price, representing part of his equity-based compensation package as a board member.

How many Pyxis Oncology (PYXS) stock options were granted and at what exercise price?

Palani Santhosh was granted 45,867 stock options with an exercise price of $1.36 per share. This price is the amount he must pay per share if he chooses to exercise the options before they expire in 2036.

When do Palani Santhosh’s Pyxis Oncology (PYXS) stock options vest?

The 45,867 stock options vest 100% on the first anniversary of the grant date. Vesting is contingent on his continued service with the company through that one-year vesting date, aligning the award with ongoing board involvement.

What is the expiration date of the new Pyxis Oncology (PYXS) stock options?

The granted stock options expire on March 24, 2036. After that date, any unexercised options become worthless, so the director must choose whether and when to exercise them before this long-term expiration deadline.

Is this Pyxis Oncology (PYXS) Form 4 a purchase or a compensation grant?

This Form 4 reflects a compensation grant, not an open-market purchase. The transaction code is “A,” indicating a grant or award of 45,867 stock options as part of the director’s equity compensation rather than a cash buy in the market.

How many Pyxis Oncology (PYXS) stock options does Palani Santhosh hold after this grant?

After this transaction, Palani Santhosh holds 45,867 stock options directly. This equals the full amount granted in the Form 4 and represents his reported derivative position from this specific option award at the time of the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Palani Santhosh

(Last) (First) (Middle)

C/O PYXIS ONCOLOGY, INC.

321 HARRISON AVENUE, 11TH FL. SUITE 1

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pyxis Oncology, Inc. [ PYXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.36	03/24/2026		A		45,867		(1)	03/24/2036	Common Stock	45,867	$0	45,867	D

Explanation of Responses:

1. The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Jitendra Wadhane, Attorney-in-Fact for Santhosh Palani	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)